

Innovation all for the patients



Roche A member of the Roche group

## Nemolizumab Shows Positive Results in Maruho's Phase 3 Study in Atopic Dermatitis

TOKYO, April 18, 2019 –[Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced today that [Maruho Co., Ltd.](#) reported results from a phase 3 study investigating the efficacy and safety of nemolizumab (CIM331) with atopic dermatitis patients 13 years of age or older who had moderate-to-severe pruritus. Nemolizumab was created by Chugai, and is currently under development in Japan by Maruho for atopic dermatitis.

Press release by Maruho issued on April 18, 2019:

Maruho Announces Positive Phase 3 Results of Nemolizumab in Patients with Atopic Dermatitis

<http://www.maruho.co.jp/english/release/>

[Note]

Press release issued on September 28, 2016:

Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market

[https://www.chugai-pharm.co.jp/english/news/detail/20160928150000\\_121.html](https://www.chugai-pharm.co.jp/english/news/detail/20160928150000_121.html)

###